IL-2 Muteins with Localized Mutations for T-reg Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for additional IL-2 muteins that can selectively modulate the activity of T-regulatory cells, as existing IL-2 muteins may not effectively promote proliferation, survival, and function of these cells while minimizing activity in non-regulatory T cells, and current therapies lack specificity in treating inflammatory disorders.
Innovation Solution
The development of peptides with specific mutations at positions 73, 76, 100, or 138, and 53, 56, 80, or 118, which are encoded by nucleic acid molecules and expressed as IL-2 muteins, these peptides or their pharmaceutical compositions are used to selectively activate T-regulatory cells and treat inflammatory disorders by stimulating STAT5 phosphorylation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If IL-2 muteins are designed to increase affinity for CD25 to compensate for reduced affinity for IL-2Rβ and IL-2Rγ, then selectivity for T-regulatory cells is improved, but the overall binding affinity and signaling efficiency may be reduced
Solution Approach 1:
The patent applies local quality by making specific localized mutations at positions 73, 76, 100, or 138 in the IL-2 molecule. These targeted mutations modify the interaction interface with CD25 to enhance selectivity for T-regulatory cells, while preserving other functional regions of the molecule. This localized modification approach allows selective enhancement of T-reg cell affinity without compromising overall molecular stability and function.
Solution Approach 2:
The patent employs parameter changes by systematically varying amino acid residues at specific positions (73, 76, 100, 138) to optimize the balance between CD25 affinity and IL-2Rβγ affinity. Through mutational analysis, the patent identifies specific parameter combinations that achieve the desired selectivity while maintaining sufficient binding affinity for effective STAT5 signaling in T-regulatory cells.
2Reliability
If mutations are introduced to enhance T-reg cell proliferation and survival, then therapeutic efficacy for inflammatory disorders is improved, but off-target effects on non-regulatory T cells may increase
Solution Approach 1:
The patent uses CD25 as an intermediary to achieve selective T-regulatory cell activation. The IL-2 muteins are designed with enhanced affinity for CD25, which is constitutively expressed at high levels on T-reg cells but at low or undetectable levels on most other T cells. This intermediary approach allows the muteins to selectively bind and activate T-reg cells through the CD25-IL-2Rβγ complex, minimizing off-target effects on non-regulatory T cells while maintaining therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These IL-2 muteins selectively enhance the proliferation, survival, and function of T-regulatory cells, thereby effectively treating inflammatory disorders with reduced activity in non-regulatory T cells, providing a therapeutic approach for autoimmune and inflammatory conditions.
Implementation Method 1
IL-2 binds three transmembrane receptor subunits: IL-2Rβ and IL-2Rγ, which together activate intracellular signaling events upon IL-2 binding, and CD25 (IL-2Rα) which serves to present IL-2 to the other 2 receptor subunits
Implementation Method 2
The signals delivered by IL-2Rβγ include those of the PI3-kinase, Ras-MAP-kinase, and STAT5 pathways. IL-2-stimulated STAT5 signaling is crucial for normal T-reg cell growth and survival
Data Source
AI summary
The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.